COGT (NASDAQ) Form 144 shows proposed 7.0M share sale after conversion
Rhea-AI Filing Summary
Cogent Biosciences reported a Form 144 notice showing proposed sales tied to a conversion: 7,000,000 shares of Common Stock associated with the conversion of Series A Convertible Preferred Stock on 03/31/2026. The filing also records 3,500,000 shares sold on 01/22/2026.
Positive
- None.
Negative
- None.
Insights
Form 144 notice documents proposed and recent secondary sales tied to a preferred conversion.
The filing lists a proposed disposal of 7,000,000 shares of Common Stock arising from the conversion of Series A Convertible Preferred Stock dated 03/31/2026. It also discloses a prior sale of 3,500,000 shares on 01/22/2026.
These are regulatory sale notices; cash‑flow treatment and beneficiary identities are not specified in the excerpt. Subsequent Form 4s or transaction confirmations would provide additional ownership and net‑proceeds details.